Medexus Pharmaceuticals: Key Stock, P/E & P/B Trends for Investors

Medexus Pharmaceuticals Inc., a company operating within the Health Care sector and specializing in the Pharmaceuticals industry, has recently been the subject of market attention. The company, which focuses on therapeutic areas such as rheumatology, autoimmune disease, specialty oncology, and pediatrics, is based in Verdun and conducts its operations primarily in North America and Canada. Its shares are traded on the Toronto Stock Exchange, and further information can be accessed through its official website at www.medexus.com .

As of February 1, 2026, Medexus Pharmaceuticals Inc. reported a closing price of 2.85 CAD. Over the past year, the company’s stock has experienced moderate volatility, with its price fluctuating between a low of 1.96 CAD on April 6, 2025, and a high of 3.90 CAD on February 4, 2025. This range indicates a trading band of approximately 2 to 4 CAD. On January 22, 2026, the company’s stock traded 0.3% higher, reflecting a modest increase in its market value.

The company’s financial metrics reveal certain insights into its market position. Medexus Pharmaceuticals Inc. has a price-to-earnings (P/E) ratio of 127.10, which suggests that its earnings are relatively low compared to its stock price. This high P/E ratio may indicate investor expectations of future growth or reflect the company’s current limited profitability. Additionally, the price-to-book (P/B) ratio stands at 1.32, indicating that the market values the company slightly above its book value. This suggests modest asset backing relative to its market valuation.

With a market capitalization of 91,748,768 CAD, Medexus Pharmaceuticals Inc. operates within a narrow price corridor, as evidenced by its recent trading activity and valuation metrics. Despite the modest daily rise reported in the latest market update, the company’s financial indicators point to a scenario of limited profitability and modest asset backing. These factors are crucial for investors and stakeholders to consider when evaluating the company’s current market position and future prospects.